logo
NT Police urged to prioritise mental health screenings: Inquest into constable's death

NT Police urged to prioritise mental health screenings: Inquest into constable's death

Warning: This story contains references to suicide and self-harm and will be distressing for some readers.
An expert in trauma and suicide has urged the Northern Territory Police Force to conduct yearly mental health screenings, telling a coronial inquest into the death of a veteran officer that better checks would likely have flagged him as an "officer at risk".
At 44 years old, after more than two decades on the front line and stints in remote communities, Constable Michael Deutrom took his own life in April 2022, devastating colleagues and casting a stark light on the toll long years in the service could take.
His death was one of three NT police suicide deaths in the first half of 2022.
Earlier in the inquest, which began in May, the coroner heard Constable Deutrom was diagnosed with post-traumatic stress disorder (PTSD) and depression around the time of his death — after years of exposure to traumatic jobs, false allegations of sexual assault against him and anxiety over losing his job.
On Friday, when the inquest continued in the Darwin Local Court, it was heard that while working in the NT remote community of Kintore, Constable Deutrom had reported he was sleeping just three hours a night, was "virtually on call 24 hours a day" and was burnt out and feeling isolated.
A year before his death in 2022, he and a colleague submitted an incident report to the NT Police Force (NTPF) stating that crime in the community was "starting to take its toll" and that he was having "adverse mental wellbeing effects" — triggering the NTPF Support and Wellbeing Unit to reach out.
According to court documents, Constable Deutrom was referred to an outside psychologist in Darwin and attended "two or three" sessions.
However, PTSD expert Professor Alexander McFarlane testified on Friday that Constable Deutrom had likely been grappling with underlying mental health issues for far longer than recognised, which underscored the need for routine psychological screening within the NTPF.
In particular, Professor McFarlane emphasised the importance of support both before and after deployment to a remote community, where isolation was especially acute.
The NTPF currently employs a single clinical psychologist, supplemented by a team of social workers and counsellors.
But the court heard that level of resourcing was inadequate to meet the mental health screening and support needs of the force.
Speaking outside court, Nathan Finn, the president of the Northern Territory Police Association, said that while NTPF policy called for officers to undergo an annual "well check", he had not received a single one during his more than two decades on the front line.
He said that despite grappling with his own job-related trauma, he was never offered a mental health check-up, and fear of being seen as unfit for duty kept him from seeking help on his own.
Above all, he said, the stigma surrounding mental health was deeply entrenched during his tenure and remained "alive and well" in the force today.
During his testimony, Professor McFarlane told the court that — while the police force started off with an "unusually healthy group of people", after many are ruled out during the initial screening process — police officers who worked more than 10 years were almost twice as likely to experience psychological distress, and six times more likely to experience symptoms of PTSD.
He said police officers were often symptomatic for "some time" before they simply could not function but, because the job typically attracted people who "naturally walk towards danger" and pride themselves on their ability to function, they often minimised health problems.
He said that given the duration of Constable Deutrom's service and exposure to traumatic jobs, the NTPF should have taken his incident report more seriously.
"There were other facts in his records … that would have pointed to him potentially being an officer at risk," Professor McFarlane told the court.
"If an officer was significantly depressed and had suicidal ideation, I think that's a circumstance where a psychiatrist should immediately be involved.
The court heard that numerous reports on suicide prevention had been handed down over the years — including the Royal Commission into Defence and Veteran Suicide, which last year recommended improved access to timely and quality mental health screenings — yet rates of police suicide had doubled across all Australian jurisdictions over the past eight years.
When asked why the rates had continued to climb, Professor McFarlane told the court that the Productivity Commission had uncovered a range of "bureaucratic inefficiencies".
"Often there is more than enough information to know about problems, but bureaucratic organisations are essentially very bad at … effectively implementing the necessary systems of care," he said.
On top of urging the introduction of routine mental health screenings, Professor McFarlane recommended that officers serving six-month stints in remote communities receive a minimum of three weeks' leave, comparable to the periods defence force personnel receive after overseas deployments.
The inquest continues this month.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Devastating': Millions of people cannot afford hygiene, cleaning basics
‘Devastating': Millions of people cannot afford hygiene, cleaning basics

News.com.au

time3 hours ago

  • News.com.au

‘Devastating': Millions of people cannot afford hygiene, cleaning basics

Four million Australians cannot afford basic personal hygiene and cleaning products, new research suggests. Up to one-in-five people are going without soap, toothpaste, pads and tampons or deodorant, results of a new survey from Good360 suggests. The researchers deem being unable to afford these essentials as 'hygiene poverty'. 'The impacts of hygiene poverty are wide ranging, with our research showing it takes a devastating toll on people's mental and physical wellbeing,' Good360 managing director Alison Covington said. 'Hygiene poverty can cause feelings of low self-esteem, embarrassment and shame, and make it difficult for people to maintain their health.' Good360 donates new and unsold clothes, homewares, toiletries and toys from hundreds of retailers to thousands of Australian charities and schools. The charity has surveyed 1000 Australians to see how many people cannot afford hygiene and cleaning products, and the results were released on Tuesday. One-in-seven survey respondents are unable to afford cleaning products, the survey finds. Women and young people are more likely to experience hygiene poverty. About 30 per cent of people aged 18 to 24 are concerned about affording hygiene and cleaning products, as are 21 per cent of women. 'Our research also highlights the significant consequences on daily life, such as people avoiding social events or other critical commitments such as work and school,' Ms Covington said. 'Eliminating hygiene poverty isn't just about ensuring people have access to toothpaste and deodorant, it's about helping people to live a dignified and healthy life. 'There should not be millions of Australians, including children, going without the basics they need to thrive,' she said. Australian-founded company QV Skincare works with Good360 to help people get basic necessities. QV head of global marketing Simone Thomassen said the findings of hygiene poverty across Australia were alarming. 'We were shocked at Good360 Australia's recent report on hygiene poverty,' she said. 'Nobody should have to experience hygiene poverty in a country like Australia. That's why we are proud to be partnering with leading charity Good360 to donate essential hygiene products to people in need.' Separate from the Good360 research, the Victorian government announced on Monday an expansion of its free pads and tampons scheme, which has put vending machines in major public markets, libraries, sporting venues and recreation centres. The $23m scheme has dispensed 90,000 hygiene packs since November 2024. 'Whether you're at a footy final or on a school excursion, you shouldn't have to worry about access to pads and tampons,' Victorian Women's Minister Natalie Hutchins said. 'We're delivering free pads and tampons in public places right across Victoria, and now we're making it a reality at some of our most iconic venues – saving Victorian families thousands of dollars every year.' The latest consumer price index data shows health costs having risen 4.1 per cent in the past year, while furnishings, household equipment and services costs have risen 1.1 per cent in the capital cities during the past three months. Food inflation is running at 3 per cent for the past 12 months. Overall, the household inflation rate has ticked up 2.1 per cent during the past year. Wages are outpacing inflation again, with the latest quarterly wage price index data showing a 3.4 per cent rise in annual terms.

Breakthrough for Rhythm's next-gen bowel test
Breakthrough for Rhythm's next-gen bowel test

The Australian

time4 hours ago

  • The Australian

Breakthrough for Rhythm's next-gen bowel test

ColoSTAT diagnostic performance consistent across colorectal cancer I to IV stages Performance meets clinical requirements for symptomatic patient testing use case Commercialisation steps underway as ColoSTAT kit transitioned to final production validation state Special Report: Rhythm Biosciences has announced that its second-generation ColoSTAT blood test detects colorectal cancer consistently across all stages of the disease, marking an important milestone as the company prepares for commercialisation later this year. Following completion of ColoSTAT Beta kit verification and validation announced in May, the Rhythm Biosciences (ASX:RHY) development team has received a batch of ColoSTAT kits produced by Quansys Biosciences using the final manufacturing process. As part of the validation process, blood samples from 300 patients, ranging from those without bowel cancer to those with stage I to IV of the disease, were tested to assess how well ColoSTAT works across all stages. While further studies will be completed, the results show the test is equally effective at detecting colorectal cancer at every stage, which is an important finding given its intended use for symptomatic patients who could have either early- or late-stage cancer tests often struggle to detect early-stage disease, so the fact that ColoSTAT performs well at this stage is seen as particularly important. The predictive cancer diagnostics technology company expects to finalise validation of the kits, algorithm, and instrumentation in the near term, ahead of a submission to the National Association of Testing Authorities (NATA) in Australia to include ColoSTAT in its ISO15189 laboratory test portfolio. NATA is Australia's primary accreditation body for laboratories and testing facilities. Commercial launch of ColoSTAT is planned for later in CY25, subject to NATA regulatory approval. Watch: CEO David Atkin's talks about early cancer detection. 'Establishing a clinically useful product' ColoSTAT is a simple, minimally invasive blood test designed for people unwilling or unable to undergo traditional screening methods for colorectal (bowel) cancer, the world's second leading cause of cancer deaths but highly treatable when detected early. The test identifies specific protein biomarkers in the blood that indicate the likelihood of colorectal cancer. The second-generation ColoSTAT blood test involved a redesign of the assay from a single-plex into a multiplex format with several objectives including: Simplify completion of the test for a routine laboratory Reduce turnaround times (TAT) Improve the quality and performance of the assay Reduce overall cost of goods for the assay Clinical advisor Dr Andy Feber said demonstrating performance across the full spectrum of neoplastic conditions was essential for a clinically useful product. 'Establishing ColoSTAT performance across the entire range of neoplastic conditions is an important requirement for a clinically useful product,' he said. 'I'm pleased to see this important milestone has been achieved.' This article was developed in collaboration with Rhythm Biosciences, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Prescient raises $9.8m to drive cancer therapies
Prescient raises $9.8m to drive cancer therapies

The Australian

time5 hours ago

  • The Australian

Prescient raises $9.8m to drive cancer therapies

Investors back Prescient with applications for $3m placement Brings total funds raised from the placement and recent SPP to $9.8m The company will use the funds to support its cancer treatment Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following a $6.9m SPP for a total $9.8m to advance its pioneering cancer treatment therapies. The clinical stage oncology company will use the funds to support the continued Phase 2 clinical development of its targeted therapy, PTX-100, which is progressing through clinical trials toward potential regulatory approval and access for patients. Two dosage levels of PTX-100 are being evaluated in an open-label design in up to 40 patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) across multiple sites in Australia, the US and Europe in its current Phase 2a study. CTCL is a rare cancer affecting white blood cells known as T cells, which normally help regulate the immune system. In CTCL, these cancerous T Cells migrate to the skin, where they grow, divide and attack uncontrollably. Treatment options remain limited for patients whose disease has relapsed or become resistant to therapy. On a mission to improve outcomes for cancer patients More than 74m shares are expected to be issued under the placement at 4c per share, the same price as the SPP. Prescient Therapeutics (ASX:PTX) CEO James McDonnell said this marks a significant step forward for the company and empowers the advancement of PTX-100 through Phase 2a development. 'I would like to thank all investors for their support of Prescient and its mission to improve outcomes for cancer patients,' he said. 'We eagerly look forward to the milestones ahead with the potential to turn the Phase 2b clinical study into a pivotal registrational study and setting the stage for PTX-100's potential market entry.' This article was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store